Trimethylamine-d9 N-oxide
(Synonyms: 三甲胺N-氧化物 d9) 目录号 : GC48206An internal standard for the quantification of trimethylamine N-oxide
Cas No.:1161070-49-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Trimethylamine-d9 N-oxide is intended for use as an internal standard for the quantification of trimethylamine N-oxide by GC- or LC-MS. Trimethylamine N-oxide (TMAO) is a metabolite of choline, phosphatidylcholine, and L-carnitine .1 It is formed by gut microbiota-mediated metabolism of choline, phosphatidylcholine, and L-carnitine to TMA followed by oxidation of TMA by flavin-containing monooxygenase 3 (FMO3) in the liver.1,2,3 Dietary administration of TMAO (0.12% w/w) increases renal tubulointerstitial fibrosis, collagen deposition, and Smad3 phosphorylation in mice and increases aortic lesion area in atherosclerosis-prone ApoE-/- mice.1,4 Plasma levels of TMAO are elevated in patients with chronic kidney disease and decreased in patients with active, compared with inactive, ulcerative colitis.1,2 Elevated plasma levels of TMAO are associated with increased risk of cardiovascular disease.4
1.Tang, W.H.W., Wang, Z., Kennedy, D.J., et al.Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney diseaseCirc. Res.116(3)448-455(2015) 2.Wilson, A., Teft, W.A., Morse, B.L., et al.Trimethylamine-N-oxide: A novel biomarker for the identification of inflammatory bowel diseaseDig. Dis. Sci.60(12)3620-3630(2015) 3.Zhang, L.S., and Davies, S.S.Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventionsGenome Med.8(1)46(2016) 4.Wang, Z., Klipfell, E., Bennett, B.J., et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature472(7341)57-63(2011)
| Cas No. | 1161070-49-0 | SDF | |
| 别名 | 三甲胺N-氧化物 d9 | ||
| Canonical SMILES | O=[N](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H] | ||
| 分子式 | C3D9NO | 分子量 | 84.2 |
| 溶解度 | Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 11.8765 mL | 59.3824 mL | 118.7648 mL |
| 5 mM | 2.3753 mL | 11.8765 mL | 23.753 mL |
| 10 mM | 1.1876 mL | 5.9382 mL | 11.8765 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。